Keywords: Skyepharma, Exparel, Flutiform, Lodotra, SKP-1052, Analgesia, Asthma, Rheumatoid arthritis, Financial

Skyepharma updates on Exparel, Flutiform and financial position

Article | 14 November 2011

Print This

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an update ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in